The report “European
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT -
Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters,
Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) -
Forecasts to 2020”, analyzes and studies the major market drivers,
restraints, challenges, and opportunities.
Browse 145 market data tables and 60 figures spread through 195 pages and in-depth TOC on “European Nuclear Medicine/Radiopharmaceuticals Market”
will receive 10% customization on this report.
This report studies the European nuclear medicine/radiopharmaceuticals
market for the forecast period of 2015 to 2020. This market is expected to
reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2%
during the forecast period (2015 to 2020).
The European nuclear medicine/radiopharmaceuticals market is
segmented on the basis of type, application, and country.
Based on type, the European nuclear
medicine/radiopharmaceuticals market is categorized into diagnostic and
therapeutic radioisotopes. In 2015, the diagnostic segment accounts for a major
share of the European nuclear medicine/radiopharmaceuticals market.
Get The PDF
The diagnostic radiopharmaceuticals market is further
segmented into SPECT and PET radioisotopes. In 2015, the SPECT segment accounts
for the largest share of the European nuclear medicine/radiopharmaceuticals
diagnostic market. The therapeutic radiopharmaceuticals market is further
segmented into beta emitters, alpha emitters, and brachytherapy. In 2015, the
beta emitters segment accounts for the largest share of the European nuclear
medicine/radiopharmaceuticals therapeutic market.
Based on application, the European nuclear
medicine/radiopharmaceuticals market is segmented into SPECT, PET, and
therapeutic applications. In 2015, the cardiology application accounts for the
largest share of European nuclear medicine SPECT market. The PET market is
dominated by oncology applications and therapeutic market is dominated by
Talk To Our Research Analysts for More Information:
On the basis of country, the market is divided into Germany,
France, Italy, U.K., Spain, Russia, and the Rest of Europe (RoE). The Rest of
Europe comprises Sweden, Switzerland, Poland, Denmark, The Netherlands, and
Belgium, among others. In 2015, Germany accounts for the largest share of the
European nuclear medicine/radiopharmaceuticals market, followed by France,
Italy, and U.K.
Factors such as increasing preference for SPECT and PET
scans, advances in radiotracers, advent of alpha radio immunotherapy-based
targeted cancer treatment, increasing incidence & mortality rate of cancer
and cardiac ailments are driving the growth of this market. However, factors
such as shorter half-life of radiopharmaceuticals, competition from
conventional diagnostic procedures are hindering the growth of this market.
Some of the major players in the European nuclear medicine market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).
Browse Related Reports:
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020.
Equipment Market by Product (SPECT (Hybrid SPECT,
Standalone SPECT), hybrid PET, & Planar Scintigraphy), Application
(Cardiology, Oncology & Neurology) & by End user (Hospitals, Imaging
Centers) - Global Forecasts to 2020.
MarketsandMarkets is the world’s No. 2 firm in terms of
annually published premium market research reports. Serving 1700 global fortune
enterprises with more than 1200 premium studies in a year, M&M is catering
to a multitude of clients across 8 different industrial verticals. We specialize
in consulting assignments and business research across high growth markets,
cutting edge technologies and newer applications. Our 850 fulltime analyst and
SMEs at MarketsandMarkets are tracking global high growth markets following the
"Growth Engagement Model – GEM". The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify most
important customers, write "Attack, avoid and defend" strategies,
identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market
research platform, "RT" connects over 200,000 markets and entire
value chains for deeper understanding of the unmet insights along with market
sizing and forecasts of niche markets. The new included chapters on Methodology
and Benchmarking presented with high quality analytical infographics in our
reports gives complete visibility of how the numbers have been arrived and
defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients
grow by providing apt business insight with our huge market intelligence
Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Visit MarketsandMarkets Blog http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets